Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 564.e1-564.e7

  Steen, Henning ^a   Lehrke, Stephanie ^b   Wiegand, Uwe K H ^c   Merten, Constanze ^c   Schuster, Lydia ^c   Richardt, Gert ^c   Kulke, Christian ^c   Gehl, Hans B ^c   Lima, Joao A ^a   Katus, Hugo A ^b   Giannitsis, Evangelos ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DIAGNOSTIC VALUE; FEMALE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HEART VENTRICLE WALL MOTION; HOSPITAL ADMISSION; HUMAN; IMAGING SYSTEM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE;

EID: 17844379981     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.023     Document Type: Article

References (25)

1. C.P. Cannon for the TIMI-18 Investigators Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N. Engl. J. Med. 344 2001 1879 1887
2. The PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N. Engl. J. Med. 338 1998 1488 1497
3. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
4. F.J. Neumann, R. Blasini, and C. Schmitt Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction Circulation 98 1998 2695 2701
5. G. Montalescot, P. Barragan, and O. Wittenberg Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344 2002 1895 1903
6. G.W. Stone, C.L. Grines, and D.A. Cox Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction N. Engl. J. Med. 346 2002 957 966
7. L.F. van den Merkhof, F. Zijlstra, and H. Olsson Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study J. Am. Coll. Cardiol. 33 1999 1528 1532
8. D.E. Cutlip, C.J. Cove, and D. Irons Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedural outcomes Am. J. Cardiol. 88 2001 62 64
9. D.P. Lee, N.A. Herity, and B.L. Hiatt Tirofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial Circulation 107 2003 1497 1501
10. F.J. Klocke, O.P. Simonetti, and R.M. Judd Limits of detection of regional differences in vasodilated flow in viable myocardium by first-pass magnetic resonance perfusion imaging Circulation 104 2001 2412 2416
11. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
12. C.M. Kramer, W.J. Rogers Jr., and D.L. Pakstis Absence of adverse outcomes after magnetic resonance imaging early after stent placement for acute myocardial infarction: a preliminary study J. Cardiovasc. Magn. Reson. 2 2000 257 261
13. M.D. Cerqueira, N.J. Weissman, and V. Dilsizian Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association Circulation 105 2002 539 542
14. S.J. Brener, L.A. Barr, and J.E. Burchenal Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators Circulation 98 1998 734 741
15. H. Ito, A. Maruyama, and K. Iwakura Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction Circulation 93 1996 223 228
16. C.M. Gibson, C.P. Cannon, and W.L. Daley TIMI frame count: a quantitative method of assessing coronary artery flow Circulation 93 1996 879 888
17. C.M. Gibson, C.P. Cannon, and S.A. Murphy Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs Circulation 101 2000 125 130
18. K.C. Wu, E.A. Zerhouni, and R.M. Judd Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction Circulation 97 1998 765 772
19. J.A. Lima, R.M. Judd, and A. Bazille Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms Circulation 92 1995 1117 1125
20. N.M. Wilke, M. Jerosch-Herold, and A. Zenovich Magnetic resonance first-pass myocardial perfusion imaging: clinical validation and future applications J. Magn. Reson. Imaging 10 1999 676 685
21. D.J. Schneider, H.C. Herrmann, and N. Lakkis Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am. J. Cardiol. 90 2002 1421 1423
22. S.S. Kabbani, A. Aggarwal, and E.F. Terrien Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am. J. Cardiol. 89 2002 647 650
23. A.M. Lincoff, R.M. Califf, and D.J. Moliterno Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators N. Engl. J. Med. 341 1999 319 327
24. D.J. Kereiakes, N.S. Kleiman, and J. Ambrose Randomized double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty J. Am. Coll. Cardiol. 27 1996 536 542
25. A. Halkin, E. Aymong, and D.A. Cox Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial) Am. J. Cardiol. 93 2004 349 353